Seelos Therapeutics Management
Seelos Therapeutics employs about 8 people. The company is managed by 7 executives with a total tenure of roughly 19 years, averaging almost 2.0 years of service per executive, having 1.14 employees per reported executive. Inspection of Seelos Therapeutics' management performance can provide insight into the company performance.
| Gopal Krishna Insider Head Operations |
| Michael Golembiewski Insider Chief Officer |
Seelos |
Seelos Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (2.6111) % which means that it has lost $2.6111 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.842) %, meaning that it created substantial loss on money invested by shareholders. Seelos Therapeutics' management efficiency ratios could be used to measure how well Seelos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Seelos Therapeutics Workforce Comparison
Seelos Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,225. Seelos Therapeutics maintains roughly 8.0 in number of employees contributing less than 1% to equities under Health Care industry.
The company has Profit Margin (PM) of 2.03 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is normal as compared to the sector avarege. Similarly, it shows Operating Margin (OM) of (8.35) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $8.35. Seelos Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Seelos Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Seelos Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Seelos Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mehra Raj over three months ago Acquisition by Mehra Raj of 2282262 shares of Seelos Therapeutics at 1.08 subject to Rule 16b-3 | ||
Mehra Raj over three months ago Acquisition by Mehra Raj of 75757 shares of Seelos Therapeutics at 1.32 subject to Rule 16b-3 | ||
O'connor Daniel J. over three months ago Acquisition by Oconnor Daniel J. of 50000 shares of Seelos Therapeutics subject to Rule 16b-3 | ||
Lian Brian over six months ago Insider Trading | ||
Smith Sandford D over a year ago Purchase by Smith Sandford D of 18200 shares of Seelos Therapeutics | ||
Richard Pascoe over a year ago Acquisition by Richard Pascoe of 1666 shares of Seelos Therapeutics subject to Rule 16b-3 |
Seelos Therapeutics Notable Stakeholders
A Seelos Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Seelos Therapeutics often face trade-offs trying to please all of them. Seelos Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Seelos Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Gopal Krishna | Head Operations | Profile | |
| Michael Golembiewski | Chief Officer | Profile | |
| Kimberly Farrand | Senior Operations | Profile | |
| Raj JD | Chairman, Founder | Profile | |
| Anthony Marciano | Chief Officer | Profile | |
| Karen Fusaro | Senior Operations | Profile | |
| Tim MD | Chief Officer | Profile |
Seelos Therapeutics Workforce Analysis
Traditionally, organizations such as Seelos Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Seelos Therapeutics within its industry.Seelos Therapeutics Manpower Efficiency
Return on Seelos Therapeutics Manpower
| Revenue Per Employee | 275.4K | |
| Revenue Per Executive | 314.7K | |
| Net Loss Per Employee | 4.7M | |
| Net Loss Per Executive | 5.4M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in income. Note that the Seelos Therapeutics information on this page should be used as a complementary analysis to other Seelos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Seelos OTC Stock
If you are still planning to invest in Seelos Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Seelos Therapeutics' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Stocks Directory Find actively traded stocks across global markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Global Correlations Find global opportunities by holding instruments from different markets |